Patents by Inventor Sung-Yun Cho

Sung-Yun Cho has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11969397
    Abstract: The present invention relates to a composition for preventing or treating transplantation rejection or a transplantation rejection disease, comprising a novel compound and a calcineurin inhibitor. A co-administration of the present invention 1) reduces the activity of pathogenic Th1 cells or Th17 cells, 2) increases the activity of Treg cells, 3) has an inhibitory effect against side effects, such as tissue damage, occurring in the sole administration thereof, 4) inhibits various pathogenic pathways, 5) inhibits the cell death of inflammatory cells, and 6) increases the activity of mitochondria, in an in vivo or in vitro allogenic model, a transplantation rejection disease model, a skin transplantation model, and a liver-transplanted patient, and thus inhibits transplantation rejection along with mitigating side effects possibly occurring in the administration of a conventional immunosuppressant alone.
    Type: Grant
    Filed: November 7, 2019
    Date of Patent: April 30, 2024
    Assignee: THE CATHOLIC UNIVERSITY OF KOREA INDUSTRY-ACADEMIC COOPERATION FOUNDATION
    Inventors: Mi-La Cho, Dong-Yun Shin, Jong-Young Choi, Chul-Woo Yang, Sung-Hwan Park, Seon-Yeong Lee, Min-Jung Park, Joo-Yeon Jhun, Se-Young Kim, Hyeon-Beom Seo, Jae-Yoon Ryu, Keun-Hyung Cho
  • Publication number: 20240119194
    Abstract: A simulation method and a simulation apparatus of roll press for secondary battery production are provided.
    Type: Application
    Filed: July 19, 2022
    Publication date: April 11, 2024
    Inventors: Shinkyu Kang, Sung Nam Cho, Youngduk Kim, Nam Hyuck Kim, Gyeong Yun Jo, Su Ho Jeon, Han Seung Kim, Junhyeok Jeon
  • Publication number: 20240105604
    Abstract: A three-dimensional (3D) semiconductor device includes a stack structure including first and second stacks stacked on a substrate. Each of the first and second stacks includes a first electrode and a second electrode on the first electrode. A sidewall of the second electrode of the first stack is horizontally spaced apart from a sidewall of the second electrode of the second stack by a first distance. A sidewall of the first electrode is horizontally spaced apart from the sidewall of the second electrode by a second distance in each of the first and second stacks. The second distance is smaller than a half of the first distance.
    Type: Application
    Filed: December 1, 2023
    Publication date: March 28, 2024
    Inventors: Sung-Hun Lee, Seokjung Yun, Chang-Sup Lee, Seong Soon Cho, Jeehoon Han
  • Publication number: 20240069535
    Abstract: The present disclosure relates to a simulation apparatus for secondary battery production.
    Type: Application
    Filed: July 14, 2022
    Publication date: February 29, 2024
    Inventors: Shinkyu KANG, Min Yong KIM, Youngduk KIM, Nam Hyuck KIM, Su Ho JEON, Min Hee KWON, Sung Nam CHO, Hyeong Geun CHAE, Gyeong Yun JO, Moon Kyu JO, Kyungchul HWANG, Moo Hyun YOO, Han Seung KIM, Daewoon JUNG, Seungtae KIM, Junhyeok JEON
  • Publication number: 20240018123
    Abstract: The present disclosure provides a compound of a chemical structure having the ability of inhibiting or disintegrating an androgen receptor (AR), or a pharmaceutically acceptable salt of the compound. The present disclosure also provides a composition comprising such a compound or a pharmaceutically acceptable salt thereof. The present disclosure provides a pharmaceutical use of a compound according to the present disclosure, a salt thereof, and a composition comprising same for the treatment or prevention of AR-related diseases. The present disclosure also provides a method for treating or preventing AR-related diseases, comprising administering to a subject in need of treatment an effective amount of a compound according to the present disclosure, a salt thereof, or a composition comprising same.
    Type: Application
    Filed: July 28, 2021
    Publication date: January 18, 2024
    Inventors: Jong Yeon HWANG, Jae Du HA, Hyun Jin KIM, Sung Yun CHO, Pilho KIM, Chong Ock LEE, Jeong Hoon KIM, Byoung Chul PARK, Sung Goo PARK, Sunhong KIM, Yuri CHOI, Yaejin WOO, Song Hee LEE, Je Ho RYU, Jungmin AHN, Ji Youn PARK, Onnuri BAE, Hanwool KIM
  • Publication number: 20220282423
    Abstract: Disclosed is a clothes drying device, including a clothes drying chamber, a dryer and a hose. A sealed space, in which a clothes hang-out set is arranged, is formed in the chamber; and the dryer includes an evaporator, an air blower, an exhaust fan, a compressor and a condenser. High-temperature heat of the dryer can be fully used by the additional chamber, and all types of clothes can be completely dried without being damaged or shrinkage. The sterilization effect is also very strong due to a higher temperature. In addition, the present disclosure has a strong dehumidification function, can be used in any place indoors or outdoors, effectively controls high temperature and high humidity generated between the condenser and a stand set of the device, ensures that high-temperature air is effectively circulated in the dryer, and can quickly and effectively realize drying of clothes.
    Type: Application
    Filed: March 4, 2021
    Publication date: September 8, 2022
    Inventor: SUNG YUN CHO
  • Publication number: 20220105188
    Abstract: The present invention relates to a target protein degradation-inducing Degraducer, a preparation method thereof, and a pharmaceutical composition for preventing or treating diseases related to EED, EZH2, or PRC2 comprising same as an active ingredient. A novel compound represented by formula 1, according to the present invention is a Degraducer compound that induces degradation of a target protein, i.e., EED or PRC2, utilizing cereblon E3 ubiquitin ligase, VHL E3 ubiquitin ligase, MDM2 E3 ubiquitin ligase, and cIAP E3 ubiquitin ligase, wherein the compound has an aspect of remarkably achieving target protein degradation-inducing activity through a ubiquitin proteasome system (UPS), and therefore there is a useful effect in that it is possible to provide a pharmaceutical composition for preventing or treating diseases or conditions related to a target protein, and a functional health food composition for preventing or improving same, comprising said compound as an active ingredient.
    Type: Application
    Filed: February 7, 2020
    Publication date: April 7, 2022
    Inventors: Jong Yeon HWANG, Jae Du HA, Sung Yun CHO, Pilho KIM, Chang Soo YUN, Hyun Jin KIM, Sung Goo PARK, Byoung Chul PARK, Jeong Hoon KIM, Sunhong KIM
  • Patent number: 11192878
    Abstract: The present disclosure relates to a novel piperidine-2,6-dione derivative and a use thereof and, more specifically, to a piperidine-2,6-dione derivative compound having a structure of a thalidomide analog. A compound of chemical formula 1 according to the present disclosure specifically binds with CRBN protein, and is involved in functions thereof. Therefore, the compound of the present disclosure can be favorably used in the prevention or treatment of leprosy, chronic graft versus host disease, an inflammatory disease, or cancer, which are caused by actions of CRBN protein.
    Type: Grant
    Filed: May 11, 2018
    Date of Patent: December 7, 2021
    Assignee: KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY
    Inventors: Jong Yeon Hwang, Jae Du Ha, Sung Yun Cho, Pil Ho Kim, Chang Soo Yun, Chi Hoon Park, Chong Ock Lee, Sang Un Choi, Joo Youn Lee, Sunjoo Ahn
  • Patent number: 11084824
    Abstract: The present invention relates to a pyrazolopyrimidine derivative, a preparation method thereof and a pharmaceutical composition comprising the same as an active ingredient for the prevention or treatment of cancer, autoimmune disease and brain disease. The pyrazolopyrimidine derivative of the present invention exhibits excellent Bruton's tyrosine kinase inhibition activity, so that it can be effectively used as a pharmaceutical composition for the prevention or treatment of cancer, autoimmune disease and Parkinson's disease.
    Type: Grant
    Filed: May 14, 2018
    Date of Patent: August 10, 2021
    Assignee: KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY
    Inventors: Pilho Kim, Sung Yun Cho, Jae Du Ha, Hyoung Rae Kim, Jong Yeon Hwang, Chang Soo Yun, Hee Jung Jung, Chi Hoon Park, Chong Ock Lee, Chang Hoon Lee, Sunjoo Ahn
  • Patent number: 11053225
    Abstract: A pyrimidine derivative compound of Chemical Formula 1, an optical isomer thereof, or a pharmaceutically acceptable salt thereof, and a composition for preventing or treating cancer comprising the same as an active ingredient. The pyrimidine derivative compound of Chemical Formula 1, the optical isomer thereof, or the pharmaceutically acceptable salt thereof has an excellent selective inhibitory effect especially against TYRO 3 among TAM receptor inhibitory effects, and thus can be used as an excellent composition of preventing or treating cancer without adverse effects resulting from the inhibition of Axl and Mer.
    Type: Grant
    Filed: May 2, 2018
    Date of Patent: July 6, 2021
    Assignee: KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY
    Inventors: Sung Yun Cho, Chang Hoon Lee, Yong Ki Min, Jong Yeon Hwang
  • Publication number: 20200199129
    Abstract: The present invention relates to a pyrazolopyrimidine derivative, a preparation method thereof and a pharmaceutical composition comprising the same as an active ingredient for the prevention or treatment of cancer, autoimmune disease and brain disease. The pyrazolopyrimidine derivative of the present invention exhibits excellent Bruton's tyrosine kinase inhibition activity, so that it can be effectively used as a pharmaceutical composition for the prevention or treatment of cancer, autoimmune disease and Parkinson's disease.
    Type: Application
    Filed: May 14, 2018
    Publication date: June 25, 2020
    Inventors: Pilho Kim, Sung Yun Cho, Jae Du Ha, Hyoung Rae Kim, Jong Yeon Hwang, Chang Soo Yun, Hee Jung Jung, Chi Hoon Park, Chong Ock Lee, Chang Hoon Lee, Sunjoo Ahn
  • Publication number: 20200087286
    Abstract: The present invention relates to a pyrimidine derivative compound, an optical isomer thereof, or a pharmaceutically acceptable salt thereof, and a composition for preventing or treating cancer comprising the same as an active ingredient. The pyrimidine derivative compound, the optical isomer thereof, or the pharmaceutically acceptable salt thereof according to the present invention has an excellent selective inhibitory effect especially against TYRO 3 among TAM receptor inhibitory effects, and thus can be used as an excellent composition of preventing or treating cancer without adverse effects resulting from the inhibition of Axl and Mer.
    Type: Application
    Filed: May 2, 2018
    Publication date: March 19, 2020
    Applicant: KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY
    Inventors: Sung Yun CHO, Chang Hoon LEE, Yong Ki MIN, Jong Yeon HWANG
  • Publication number: 20200062730
    Abstract: The present disclosure relates to a novel piperidine-2,6-dione derivative and a use thereof and, more specifically, to a piperidine-2,6-dione derivative compound having a structure of a thalidomide analog. A compound of chemical formula 1 according to the present disclosure specifically binds with CRBN protein, and is involved in functions thereof. Therefore, the compound of the present disclosure can be favorably used in the prevention or treatment of leprosy, chronic graft versus host disease, an inflammatory disease, or cancer, which are caused by actions of CRBN protein.
    Type: Application
    Filed: May 11, 2018
    Publication date: February 27, 2020
    Inventors: Jong Yeon HWANG, Jae Du HA, Sung Yun CHO, Pil Ho KIM, Chang Soo YUN, Chi Hoon PARK, Chong Ock LEE, Sang Un CHOI, Joo Youn LEE, Sunjoo AHN
  • Patent number: 10369149
    Abstract: The present invention relates to a 4-(2-amino-tetrahydronaphthaleneyl)pyrimidine derivative, a preparation method thereof, and a pharmaceutical composition for the prevention or treatment of cancer comprising the same as an active ingredient. The 4-(2-amino-tetrahydronaphthaleneyl)pyrimidine derivative, the optical isomer thereof, or the pharmaceutically acceptable salt thereof of the present invention is very effective in suppressing anaplastic lymphoma kinase (ALK) activity and as a result it can improve the effectiveness of treatment on cancer cells having anaplastic lymphoma kinase (ALK) fusion proteins such as EML4-ALK and NPM-ALK, so that it can be effectively used as a pharmaceutical composition for preventing or treating cancer.
    Type: Grant
    Filed: December 30, 2015
    Date of Patent: August 6, 2019
    Assignee: KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY
    Inventors: Jong Yeon Hwang, Hyoung Rae Kim, Jae Du Ha, Sung Yun Cho, Hee Jung Jung, Pilho Kim, Chang Soo Yun, Chong Ock Lee, Chi Hoon Park, Chong Hak Chae, Sunjoo Ahn
  • Patent number: 10100019
    Abstract: The present invention relates to a N2-(2-methoxyphenyl)pyrimidine derivative, a preparation method thereof, and a pharmaceutical composition for the prevention or treatment of cancer comprising the same as an active ingredient. The N2-(2-methoxyphenyl)pyrimidine derivative, the optical isomer thereof, or the pharmaceutically acceptable salt thereof of the present invention is very effective in suppressing anaplastic lymphoma kinase (ALK) activity and as a result it can improve the effectiveness of treatment on cancer cells having anaplastic lymphoma kinase (ALK) fusion proteins such as EML4-ALK and NPM-ALK, so that it can be effectively used as a pharmaceutical composition for preventing or treating cancer.
    Type: Grant
    Filed: April 6, 2016
    Date of Patent: October 16, 2018
    Assignee: Korea Research Institute of Chemical Technology
    Inventors: Pilho Kim, Hyoung Rae Kim, Sung Yun Cho, Jae Du Ha, Hee Jung Jung, Chang Soo Yun, Jong Yeon Hwang, Chi Hoon Park, Chong Ock Lee, Sunjoo Ahn, Chong Hak Chae
  • Patent number: 10053458
    Abstract: The present invention relates to a pyrimidine-2,4-diamine derivative or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition for prevention or treatment of cancer comprising the same as an effective ingredient. A compound according to the present invention has the good effect of inhibiting anaplastic lymphoma kinase (ALK) activity, whereby a therapeutic effect on cancer cells having an anaplastic lymphoma kinase (ALK) fusion protein such as EML4-ALK, NPM-ALK, etc. can be enhanced and it is expected that a recurrence of cancer will be effectively inhibited. As such, the compound can be effectively used in a pharmaceutical composition for prevention or treatment of cancer.
    Type: Grant
    Filed: May 21, 2015
    Date of Patent: August 21, 2018
    Assignee: KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY
    Inventors: Chang Soo Yun, Hyoung Rae Kim, Sung Yun Cho, Hee Jung Jung, Kwangho Lee, Chong Hak Chae, Chong Ock Lee, Chi Hoon Park, Pilho Kim, Jong Yeon Hwang, Jae Du Ha, Sun Joo Ahn
  • Publication number: 20180111905
    Abstract: The present invention relates to a N2-(2-methoxyphenyl)pyrimidine derivative, a preparation method thereof, and a pharmaceutical composition for the prevention or treatment of cancer comprising the same as an active ingredient. The N2-(2-methoxyphenyl)pyrimidine derivative, the optical isomer thereof, or the pharmaceutically acceptable salt thereof of the present invention is very effective in suppressing anaplastic lymphoma kinase (ALK) activity and as a result it can improve the effectiveness of treatment on cancer cells having anaplastic lymphoma kinase (ALK) fusion proteins such as EML4-ALK and NPM-ALK, so that it can be effectively used as a pharmaceutical composition for preventing or treating cancer.
    Type: Application
    Filed: April 6, 2016
    Publication date: April 26, 2018
    Applicant: KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY
    Inventors: Pilho Kim, Hyoung Rae Kim, Sung Yun Cho, Jae Du Ha, Hee Jung Jung, Chang Soo Yun, Jong Yeon Hwang, Chi Hoon Park, Chong Ock Lee, Sunjoo Ahn, Chong Hak Chae
  • Publication number: 20180104242
    Abstract: The present invention relates to a 4-(2-amino-tetrahydronaphthaleneyl)pyrimidine derivative, a preparation method thereof, and a pharmaceutical composition for the prevention or treatment of cancer comprising the same as an active ingredient. The 4-(2-amino-tetrahydronaphthaleneyl)pyrimidine derivative, the optical isomer thereof, or the pharmaceutically acceptable salt thereof of the present invention is very effective in suppressing anaplastic lymphoma kinase (ALK) activity and as a result it can improve the effectiveness of treatment on cancer cells having anaplastic lymphoma kinase (ALK) fusion proteins such as EML4-ALK and NPM-ALK, so that it can be effectively used as a pharmaceutical composition for preventing or treating cancer.
    Type: Application
    Filed: December 30, 2015
    Publication date: April 19, 2018
    Applicant: KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY
    Inventors: Jong Yeon HWANG, Hyoung Rae KIM, Jae Du HA, Sung Yun CHO, Hee Jung JUNG, Pilho KIM, Chang Soo YUN, Chong Ock LEE, Chi Hoon PARK, Chong Hak CHAE, Sunjoo AHN
  • Publication number: 20170145007
    Abstract: The present invention relates to a pyrimidine-2,4-diamine derivative or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition for prevention or treatment of cancer comprising the same as an effective ingredient. A compound according to the present invention has the good effect of inhibiting anaplastic lymphoma kinase (ALK) activity, whereby a therapeutic effect on cancer cells having an anaplastic lymphoma kinase (ALK) fusion protein such as EML4-ALK, NPM-ALK, etc. can be enhanced and it is expected that a recurrence of cancer will be effectively inhibited. As such, the compound can be effectively used in a pharmaceutical composition for prevention or treatment of cancer.
    Type: Application
    Filed: May 21, 2015
    Publication date: May 25, 2017
    Inventors: Chang Soo YUN, Hyoung Rae KIM, Sung Yun CHO, Hee Jung JUNG, Kwangho LEE, Chong Hak CHAE, Chong Ock LEE, Chi Hoon PARK, Pilho KIM, Jong Yeon HWANG, Jae DU HA, Sun Joo AHN
  • Patent number: 9403831
    Abstract: The present invention relates to a novel triazolopyrazine derivative or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition containing the same as an active ingredient for preventing or treating hyper proliferative disorder. The present invention can be useful as a therapeutic agent for various hyper proliferative disorders associated with excessive cell proliferation and growth caused by abnormal kinase activity, such as cancer, psoriasis, rheumatoid arthritis, and diabetic retinopathy, by efficiently inhibiting c-Met tyrosine kinase activity.
    Type: Grant
    Filed: September 30, 2013
    Date of Patent: August 2, 2016
    Assignees: KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY, HANDOK INC.
    Inventors: Hee Jung Jung, Jae Du Ha, Sung Yun Cho, Hyoung Rae Kim, Kwang Ho Lee, Chong Ock Lee, Sang Un Choi, Chi Hoon Park